FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990141231> ?p ?o ?g. }

• W2990141231 abstract "Purpose: To assess the expected value (EVPI and EVSI and EVIC) of a proposed clinical trial of patients with early-stage breast cancer with the following aims (1) surveillance using currently available CA15-3/CA 27.29 biomarkers to detect recurrence (2) biobank creation of serial blood specimens that could be used to discover more accurate biomarkers for detecting breast cancer recurrence. Method: We developed a decision-analytic model comparing the addition tumor biomarker to standard surveillance in patients with early-stage breast cancer. Model parameters and uncertainties, including quality-of-life indicators, were derived from literature values, clinical experts and multidisciplinary stakeholders. Our model also incorporated uncertainties in patient/provider adherence to recommended guidelines. The affected population was estimated from SEER data and discounted over a 10-year time horizon. Expected values were assessed at a $150K/QALY threshold in the base-case. The expected-value-of-individualized care (EVIC) i.e., total potential value of a biobank, was estimated by evaluating the impact of developing an improved diagnostic using biobank samples. Limiting assumptions were then applied to the EVIC to obtain a range of conservative biobank values. Result: The standard care strategy was found to be cost-effective. However, the acceptability probability was only 55% with individual and population EVPI values of $4,600 and $1.7 billion (10-year time horizon). The EVSI for the trial ranged from $0.25 to $1.3 billion for trial sizes from 100 to 9,000 patients. Key uncertainties dominating EVPI and EVSI magnitudes were impact on survival through earlier detection of breast cancer, and quality-of-life impacts of testing including false positives, burden of increased testing, and deviations of uptake from clinical guidelines. The value of a biobank ranged from $136–700 million under a range of scenarios. Conclusion: Our findings indicate that additional research assessing the use of breast cancer recurrence biomarkers and consequent earlier treatment could be highly valuable. Given the paucity of prior clinical data evaluating the effectiveness of existing markers, even a relatively small trial could provide substantial societal value. Model analysis suggests that trials focused on reducing uncertainty in survival and quality-of-life impact associated with breast cancer tumor marker testing represent the most effective investments. Efforts to increase adherence to guidelines in real-world settings can also offer substantial health care system dividends. Considerable value may also be derived through trial patient samples stored in a biobank." @default.
• W2990141231 created "2019-12-05" @default.
• W2990141231 creator A5025364402 @default.
• W2990141231 creator A5032696513 @default.
• W2990141231 creator A5036802680 @default.
• W2990141231 creator A5037848674 @default.
• W2990141231 creator A5068073076 @default.
• W2990141231 creator A5085042140 @default.
• W2990141231 creator A5087861262 @default.
• W2990141231 creator A5088225928 @default.
• W2990141231 date "2011-01-01" @default.
• W2990141231 modified "2023-09-27" @default.
• W2990141231 title "Evaluating a proposed swog trial of breast cancer tumor markers: A value of research and biobank analysis" @default.
• W2990141231 hasPublicationYear "2011" @default.
• W2990141231 type Work @default.
• W2990141231 sameAs 2990141231 @default.
• W2990141231 citedByCount "0" @default.
• W2990141231 crossrefType "journal-article" @default.
• W2990141231 hasAuthorship W2990141231A5025364402 @default.
• W2990141231 hasAuthorship W2990141231A5032696513 @default.
• W2990141231 hasAuthorship W2990141231A5036802680 @default.
• W2990141231 hasAuthorship W2990141231A5037848674 @default.
• W2990141231 hasAuthorship W2990141231A5068073076 @default.
• W2990141231 hasAuthorship W2990141231A5085042140 @default.
• W2990141231 hasAuthorship W2990141231A5087861262 @default.
• W2990141231 hasAuthorship W2990141231A5088225928 @default.
• W2990141231 hasConcept C112930515 @default.
• W2990141231 hasConcept C116567970 @default.
• W2990141231 hasConcept C121332964 @default.
• W2990141231 hasConcept C121608353 @default.
• W2990141231 hasConcept C126322002 @default.
• W2990141231 hasConcept C143998085 @default.
• W2990141231 hasConcept C144024400 @default.
• W2990141231 hasConcept C177713679 @default.
• W2990141231 hasConcept C185592680 @default.
• W2990141231 hasConcept C19527891 @default.
• W2990141231 hasConcept C22467394 @default.
• W2990141231 hasConcept C2781197716 @default.
• W2990141231 hasConcept C28761237 @default.
• W2990141231 hasConcept C2908647359 @default.
• W2990141231 hasConcept C3019080777 @default.
• W2990141231 hasConcept C36289849 @default.
• W2990141231 hasConcept C530470458 @default.
• W2990141231 hasConcept C535046627 @default.
• W2990141231 hasConcept C55493867 @default.
• W2990141231 hasConcept C60644358 @default.
• W2990141231 hasConcept C62520636 @default.
• W2990141231 hasConcept C64332521 @default.
• W2990141231 hasConcept C71924100 @default.
• W2990141231 hasConcept C86803240 @default.
• W2990141231 hasConcept C99454951 @default.
• W2990141231 hasConceptScore W2990141231C112930515 @default.
• W2990141231 hasConceptScore W2990141231C116567970 @default.
• W2990141231 hasConceptScore W2990141231C121332964 @default.
• W2990141231 hasConceptScore W2990141231C121608353 @default.
• W2990141231 hasConceptScore W2990141231C126322002 @default.
• W2990141231 hasConceptScore W2990141231C143998085 @default.
• W2990141231 hasConceptScore W2990141231C144024400 @default.
• W2990141231 hasConceptScore W2990141231C177713679 @default.
• W2990141231 hasConceptScore W2990141231C185592680 @default.
• W2990141231 hasConceptScore W2990141231C19527891 @default.
• W2990141231 hasConceptScore W2990141231C22467394 @default.
• W2990141231 hasConceptScore W2990141231C2781197716 @default.
• W2990141231 hasConceptScore W2990141231C28761237 @default.
• W2990141231 hasConceptScore W2990141231C2908647359 @default.
• W2990141231 hasConceptScore W2990141231C3019080777 @default.
• W2990141231 hasConceptScore W2990141231C36289849 @default.
• W2990141231 hasConceptScore W2990141231C530470458 @default.
• W2990141231 hasConceptScore W2990141231C535046627 @default.
• W2990141231 hasConceptScore W2990141231C55493867 @default.
• W2990141231 hasConceptScore W2990141231C60644358 @default.
• W2990141231 hasConceptScore W2990141231C62520636 @default.
• W2990141231 hasConceptScore W2990141231C64332521 @default.
• W2990141231 hasConceptScore W2990141231C71924100 @default.
• W2990141231 hasConceptScore W2990141231C86803240 @default.
• W2990141231 hasConceptScore W2990141231C99454951 @default.
• W2990141231 hasIssue "2" @default.
• W2990141231 hasLocation W29901412311 @default.
• W2990141231 hasOpenAccess W2990141231 @default.
• W2990141231 hasPrimaryLocation W29901412311 @default.
• W2990141231 hasRelatedWork W1765673603 @default.
• W2990141231 hasRelatedWork W1977112344 @default.
• W2990141231 hasRelatedWork W1984100426 @default.
• W2990141231 hasRelatedWork W2005299121 @default.
• W2990141231 hasRelatedWork W2055306526 @default.
• W2990141231 hasRelatedWork W2079429420 @default.
• W2990141231 hasRelatedWork W2104859076 @default.
• W2990141231 hasRelatedWork W2141229620 @default.
• W2990141231 hasRelatedWork W2152157592 @default.
• W2990141231 hasRelatedWork W2172201105 @default.
• W2990141231 hasRelatedWork W2186417810 @default.
• W2990141231 hasRelatedWork W2416704090 @default.
• W2990141231 hasRelatedWork W2617169454 @default.
• W2990141231 hasRelatedWork W2797712401 @default.
• W2990141231 hasRelatedWork W2801327923 @default.
• W2990141231 hasRelatedWork W2884541682 @default.
• W2990141231 hasRelatedWork W2965569600 @default.
• W2990141231 hasRelatedWork W3120659305 @default.
• W2990141231 hasRelatedWork W3141348703 @default.
• W2990141231 hasRelatedWork W3211623913 @default.

• next